SecBot SecBot
6-K ·Filed Aug 12, 2026

GMAB

GENMAB A/S
NEUTRAL
Impact 2/10
Horizonimmediate Processed3mo ago SEC0001434265-26-000113
Actionable Insight • Neutral

This is a routine administrative filing with no actionable trading signal. Monitor upcoming H1 2026 earnings release for financial performance updates.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$31.42
T+0 close · Aug 12, 2026 · via day close
Latest settled
+75.43%
T+60 · $55.12
Vs SPY
+80.31%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 12 $31.42entry
  2. T+1 · 3mo ago −0.25%α −0.95% · $31.34
  3. T+5 · 3mo ago +8.56%α +9.01% · $34.11
  4. T+20 · 2mo ago +2.58%α +4.48% · $32.23
  5. T+60 · 12d ago +75.43%α +80.31% · $55.12
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Genmab A/S filed its updated Articles of Association on August 11, 2026, via a Form 6-K on August 12, 2026. The filing is a routine corporate governance update, renewing existing authorizations for the Board of Directors to issue shares and warrants for employee incentive programs through March 2029/2030. The document details the terms of employee warrant schemes, including vesting schedules and exercise prices. No material financial data, changes in business operations, or new strategic initiatives were disclosed. The filing is administrative in nature and does not contain information that would materially impact the company's stock price.

Key Facts

  • Genmab filed an updated set of Articles of Association on August 11, 2026.
  • The Board of Directors' authorization to increase share capital without pre-emption rights (up to DKK 6.6M) is renewed through March 12, 2029.
  • The Board of Directors' authorization to issue convertible debt instruments (up to DKK 3M nominal) is renewed through March 12, 2029.
  • Multiple employee warrant schemes are detailed, with grants issued from 2017 through June 2026, all with exercise prices at or above market price at time of grant.
  • The filing is a routine corporate governance update with no financial results or operational changes.

Financial Impact

No financial impact. The filing is a routine update of corporate governance documents with no new financial data.

Risk Factors

  • No material risks identified from this filing.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
81% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 10 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (GMAB), Batch item 10001434265-26-000113
Document: gmab_20260812x6k.htm0001434265-26-000113
Document: 0001434265-26-000113-index-headers.html0001434265-26-000113
Document: 0001434265-26-000113-index.html0001434265-26-000113
Document: 0001434265-26-000113.txt0001434265-26-000113
6-K Filing (GMAB), Batch item 60001434265-26-000113
Document: gmab_20260812x6k.htm0001434265-26-000113
Document: 0001434265-26-000113-index-headers.html0001434265-26-000113
Document: 0001434265-26-000113-index.html0001434265-26-000113
Document: 0001434265-26-000113.txt0001434265-26-000113

US Market Status

Market Closed · Opens in 9h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 12, 2026